Takeda expands Phase III ixazomib MM program to Japan
This article was originally published in Scrip
Takeda has begun enrolling the first patients in Japan into the ongoing TOURMALINE-MM1 Phase III global study with potential Velcade successor ixazomib citrate (MLN9708), to generate data in support of a planned approval filing in the country.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.